Teng-Kuang Yeh, Ph. D.
Institute of Biotechnology and Pharmaceutical Research
EDUCATIONPh.D. Pharmaceutics, The Ohio State University, USA.
M.S. Pharmaceutics and Pharmaceutical Chemistry, The Ohio State University, USA
B.S., Pharmacy, Taipei Medical University, Taiwan
PROFESSIONAL EXPERIENCESAssociate Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan
Research Associate, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taiwan
Research Scientist, Optimum Therapeutics, LLC, Columbus, Ohio, USA
Postdoctoral Research Associate, The Ohio State University, USA
Graduate Research Associate, The Ohio State University, USA
Research Investigator, China Chemical and Pharmaceutical Research Center
RESEARCH INTERESTSDr. Yeh's research interests are in the areas of preclinical and clinical
pharmacokinetics, drug metabolism, drug interaction, drug delivery and
biopharmaceutics. The projects include determination of the physical and chemical properties of a therapeutic entity, method development and validation of sensitive and specific analytical techniques for the identification and quantitation of new chemical entities and/or drugs and their metabolites in biological matrices, characterizing the in vivo pharmacokinetics and metabolism of new chemical entities and/or drugs using animal models, scaling preclinical and in-vitro data to predict events in humans for preliminary assessment of safe exposure levels, determination of the metabolite profiles of drug candidates using hepatocytes and liver microsomes containing a single enzyme, identify Phase I or Phase II enzymes responsible for metabolite formation, predict drug interactions due to inhibition or induction of drug metabolizing enzymes, regulation and function of drug-metabolizing enzymes, particularly with an interest in elucidating mechanisms of drug-drug, herb-drug and food-drug interactions and studying the role of drugs and natural products in drug induced hepatotoxicity and in cancer chemotherapy, development of intravenous and extravascular dosage formulations for synthetic organic molecules to optimize their therapeutic values, and improving the drug delivery system of drugs through the use of novel formulations (i.e. micro-and nanoparticles) to help localize the drug to target sites and minimize drug toxicity.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSDr. Yeh is currently involved in the early stage new small molecular entities discovery at Division of Biotechnology and Pharmaceutical Research (DBPR). He has contributed to help DBPR drug discovery team to the success of several discovery projects leading to the selection and/or termination of development candidate(s) from the pharmacokinetics and drug metabolism aspects. A significant portion of his present and previous researches has been to develop novel assay methods and formulations to evaluate pharmacokinetic properties and drug metabolites of the small chemical entities and drugs, and to integrate the in vitro and in vivo correlation to extrapolate into human clinical trials.
SELECTED PUBLICATIONS1.Chang YW, Yao HT, Chao YS, Yeh TK*. Rapid and sensitive determination of fentanyl in dog plasma by on-line solid-phase extraction integrated with a hydrophilic column coupled to tandem mass spectrometry. J. Chromatogr. B., 857 (2): 195-201, 2007. (*=Corresponding author).
2.Chang YW, Yao HT, Hsieh SH, Lu TJ, Yeh TK*. Quantitative determination of salidroside in rat plasma by on-line solid-phase extraction integrated with high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B., 857 (1): 164-169, 2007 (*=Corresponding author).
3.Yang RSH, Chang LW, Wu JP, Tsai MH, Wang HJ, Kuo YC, Yeh TK,Yang CS and Lin P. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect., 15 (9):1339-1434, 2007.
4.Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res., 24(9): 1691-1701.2007.
5.Yao HT, Wu YS, Chang YW, Hsieh HP, Chen WC, Lan SJ, Chen CT, Chao YS, Chang L, Sun HY, Yeh TK*. Biotransformation of 6-Methoxy-3- (3',4',5'- trimethoxy-benzoyl)- 1H -indole (BPR0L075), a Novel Antimicrotubule Agent, by Mouse, Rat, Dog, and Human Liver Microsomes. Drug Metab Dispos., 35 (7): 1042-1049, 2007 (*=Corresponding author).
6.Chang YW, Chen WC, Lin KT, Chang L, Yao HT, Hsieh HP, Lan SJ, Chen CT, Chao YS and Yeh TK*. Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: application to a pharmacokinetic study. J. Chromatogr. B., 846 (1-2):162-168, 2007(*=Corresponding author).